Depression is the most common psychiatric comorbidity among people living with HIV/AIDS (PLWHA). Little is known about the comparative effectiveness between different types of antidepressants used to treat depression in this population. We compared the effectiveness of dual-action and single-action antidepressants in PLWHA for achieving remission from depression.
Introduction 2
Depression is the most common psychiatric disorder among people living with HIV/AIDS (Nanni et al., 2015) . People living with HIV/AIDS (PLWHA) are two to four times as likely to suffer from depression compared to the general population (Kaaya et al., 2013; Nanni et al., 2015; Wendorf and Mosack, 2013) . Depression is associated with suboptimal antiretroviral treatment (ART) adherence, accelerated HIV disease progression, decreased quality of life, increased morbidity and premature mortality (Nanni et al., 2015) .
Given the consequences of depression for PLWHA, depression treatment is extremely important. One common treatment approach is antidepressant medication.
Several antidepressants with different pharmacological properties are considered appropriate for 1 st line treatment in PLWHA. Currently selective-serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed class of antidepressants to PLWHA (Freudenreich et al., 2010) . SSRIs (e.g. citalopram) are considered to be single-action antidepressants because they impact only one neurotransmitter known as serotonin (Delgado, 2009; Rakesh, 2004) . Dual-action antidepressants are another category of medications used as treatment for depression in PLWHA. Dual-action antidepressants differ from those with single-action in that they impact two neurotransmitters thought to be associated with depression (i.e. serotonin, norepinephrine, or dopamine) at the same time (Rakesh, 2004) . Examples of dualaction antidepressants considered appropriate for PLWHA include serotonin-4 norepinephrine reuptake inhibitors (e.g. venlafaxine), bupropion and mirtazapine (Adams et al., 2012) .
Randomized controlled trials have demonstrated that antidepressants have high levels of efficacy in PLWHA (Hill and Lee, 2013; Himelhoch and Medoff, 2005; . However, there is limited literature that has compared the effectiveness of the different antidepressants currently used to treat PLWHA for depression. In fact we found only one study that compared a single-action and dual-action antidepressant commonly used today among PLWHA (Patel, 2013) . This randomized open label eightweek trial compared mirtazapine (dual-action) to escitalopram (single-action) in a sample of seventy HIV positive patients. While remission and response rates did not differ statistically, the median Hamilton Rating Scale for Depression (HAM-D) score at eight weeks was significantly lower for mirtazapine (median=4) compared to escitalopram (median=12) with a p-value of <0.001.
In contrast, substantial effort has been given to comparing effectiveness between antidepressants among populations without HIV infection (Bauer et al., 2009; Bradley and Lenox-Smith, 2013; Delgado, 2009; Gartlehner et al., 2011; Grunebaum et al., 2013; Rakesh, 2004; Richelson, 2013) . These studies are based on the hypothesis that broader spectrum antidepressants with dual action may be more effective than those with single action because depression can arise out of dysfunction along multiple neurotransmitters pathways (Delgado, 2009; Rakesh, 2004) . While earlier studies revealed potential advantages for dual-action antidepressants (Bauer et al., 2009; Delgado, 2009; Rakesh, 2004) , results from a more recent meta-analysis analysis concluded that there were no significant differences according to type of medication 5 (Gartlehner et al., 2011) . However, there was a paucity of evidence specific to PLWHA contained in the meta-analysis, therefore caution is warranted when generalizing the conclusion to those with HIV-infection.
In fact, more nuanced findings from general population studies suggests that further investigation of the comparative effectiveness of dual-vs. single-action antidepressants is warranted in PLWHA. First, mirtazapine is known to have a faster onset of action compared to single-action SSRIs (Gartlehner et al., 2011) . While timely alleviation of depressive symptoms is important for all people with depression, it is especially salient to PLWHA given the negative HIV/AIDS related health consequences associated with this psychiatric condition. Secondly, bupropion has a lower risk of sexual side effects compared to single-action SSRIs which may lead to better antidepressant treatment adherence (Gartlehner et al., 2011) and therefore better response. PLWHA have been shown to be at higher risk of sexual dysfunction, independent of antidepressant exposure (Bouhnik et al., 2008) , therefore in order to avoid additional exascerbation of this problem, bupropion may be more advantageous in the context of HIV infection. Finally, in a systematic review conducted in 2013, authors found sufficient evidence to conclude that SNRIs may have greater efficacy than SSRIs for more severe cases of depression. (Bradley and Lenox-Smith, 2013) These findings are relevant to PLWHA given depression in HIV/AIDS is typically chronic and often accompanied by additional psychiatric diagnoses (e.g. anxiety, substance use disorder), which in turn lends itself to greater severity in depressive symptomology.
Despite the potential advantages from dual-action antidepressants for PLWHA highlighted above, a significant gap remains in research comparing antidepressants in 6 PLWHA. To address this gap, we compared the effectiveness of dual-action and singleaction antidepressants for achieving remission from depression among PLWHA. We also assessed comparative effectiveness for depression symptom severity. Results from this study have the potential to generate much needed comparative evidence that can reduce uncertainty for a physician when choosing an antidepressant to treat depression in PLWHA. We hypothesized that dual-action antidepressants would be more effective than single-action antidepressants for achieving remission and reducing depression symptoms.
Methods

Data and study population
This comparative effectiveness study used data from the Center for AIDS We employed a new-user approach (Ray, 2003) to identify antidepressant treatment episodes with a minimum washout period of 90-days; meaning participants received no treatment with any antidepressant considered in this analysis during a period of at least 90 days prior to the treatment episode initial prescription date (index date). Additionally, a treatment episode consisted of a twelve-month follow-up period.
We limited our analysis to the patient's first occurring treatment episode with the earliest index date, therefore a patient could contribute only one observation. Treatment episodes were separated into two comparison groups based on the number of neurotransmitters impacted by the antidepressant. Dual-action antidepressants were defined as the intervention group and included mirtazapine, bupropion, desvenlafaxine, duloxetine or venlafaxine (Delgado, 2009; Rakesh, 2004) . Single-action (SSRIs)
antidepressants were used as the active comparator group. Single-action antidepressants included citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline (Delgado, 2009; Rakesh, 2004) .
The primary analysis used an intent-to-treat approach, in which participants were analyzed according to the initial antidepressant prescribed, regardless of whether the participant remained on that antidepressant, discontinued, augmented or switched medications during the twelve-month follow-up period. Since discontinuation, switching and augmenting can introduce bias to the estimates of treatment effects, we conducted a sensitivity analysis limiting the sample to per protocol treatment episodes (Brookhart et al., 2013) . Per protocol treatment episodes were defined as continuous receipt of the original medication without switching or augmenting for the entire twelve-month followup period. 
Measures
The primary outcome, remission from depression (yes/no), was measured using the Patient Healthcare Questionnaire-9 (PHQ-9), a previously validated instrument for 9 assessing depression severity on a scale from 0-27 (Kroenke et al., 2001) . A score of <5 was considered to be remission based on the defined severity levels of the PHQ-9 (Kroenke et al., 2001 ). The mean difference in depression symptom severity, a secondary outcome, was defined as the difference in the raw PHQ-9 score between treatment groups. Only the last observation that occurred during the twelve-month follow-up period was used in the analysis in order to allow for the maximum amount of therapeutic exposure.
Several categories of pre-index date covariates were used to help control for any 
Confounding and treatment episodes with missing outcomes
We used inverse probability of treatment (IPT) weights (Austin and Stuart, 2015) to balance comparison groups on baseline (pre-index date) covariates that had the potential for confounding. IPT weights were computed with a two-step process. First we used logistic regression to model the predicted probability of receiving the intervention (dual-action antidepressants). Second, we took the inverse of the predicted probabilities from the logistic regression model to derive the IPT weights. Balance between treatment groups on baseline covariates was assessed using standardized differences in mean and frequencies (Austin and Stuart, 2015) . We considered a standard difference of ≤0.25 to be indicative of good balance on the covariate (Harder et al., 2010) .
While 1,175 intent-to-treat treatment episodes were identified, only 494 (42%)
had an observed PHQ-9 during the 12-month follow-up period. If PHQ-9 "missingness" is related to the treatment group and the value of the outcome, then estimates limited to complete cases (treatment episodes with a PHQ-9 at follow-up) will be biased. We chose to address this potential bias by using inverse probability of observation weights (Seaman and White, 2013) . Inverse probability of observation (IPO) weights were calculated with the same process as IPT weights, the only difference being weights were modeled as the predicted probability of having an observed PHQ-9 during the follow-up period.
We then multiplied the IPT and IPO weights to create a unified inverse probability of treatment and observation (IPTO) weight (Cole et al., 2010) . By applying the IPTO weights to our sample, we created a theoretical pseudo-population that approximates what we would have observed if: (1) All 1,175 treatment episodes had an observed PHQ-9 at follow-up and; 2) treatment selection was independent of the observed baseline covariates included in the IPT model. All weights (IPT, IPO and IPTO) were stabilized per Harder et al. (2010) and met distributional recommendations (Harder et al. 2010 ). Details regarding the IPT, IPO and IPTO models are provided in the Supplemental Online Appendix.
Statistical analysis
Statistical analyses were conducted using Statistical Analysis Software (SAS®) version 9.4 (SAS®, 2012). We estimated the relative odds of achieving remission with SAS ® PROC GENMOD, whereby a generalized linear model was fitted with a binomial distribution and logit link. Additionally, we fitted a generalized linear model with a normal distribution and identity link to estimate the mean difference in depression symptom severity. Robust standard errors were used to account for potential bias in standard error estimates that can arise when using inverse probability weighting methods.
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Results
Intent-to-treat treatment episode characteristics
Citalopram (single-action) and bupropion (dual-action) were the most commonly prescribed antidepressants (see Supplemental Online Appendix). Approximately 19% of all patients had a history of being treated with single-action antidepressants prior to the current treatment episode, while 11% had prior exposure to dual-action antidepressants (Table 1 ). The mean age at the index date was 38 (standard deviation [SD] = 10 years) with the majority of subjects being white non-Hispanic males. Most subjects (87%) were receiving ART on the index date and based on the last lab result in the washout period, the mean CD4 T-cell count was 484 (SD = 281) and 69% of the patients were virally suppressed. About one third of the patients had a diagnosis of anxiety and a documented history of drug use. In the dual-action group, patients were more likely to have received dual-action antidepressant therapy prior to the current treatment episode, to have seen a psychiatrist during the washout period, to be white non-Hispanic, to be virally suppressed during the washout period and to have a history of drug use compared to patients in the single-action group. IPTO weighting had little influence on our results, and were similar to unweighted analyses. For simplicity we only report the estimates from IPTO models.
Intent-to-treat analysis
After applying IPT weights, the standardized differences for all baseline covariates were below the 0.25 threshold, ranging from 0.002 to 0.066 (Table 1) . The IPTO weighted frequency of remission (32% vs 32%) and mean depression severity (9.2 vs 8.1) at follow-up were not statistically different between dual-action and single-action treatment episodes, respectively (Table 1) . Results of the IPTO weighted generalized linear models for both outcomes were not statistically significant ( Table 2 ).
The odds ratio for achieving remission was 1.02 (95% CI 0.63-1.67). The mean difference in depression symptom severity between groups was 1.1 units on the PHQ-9's 0-27 scale (95% CI -0.4-2.6).
Per-protocol sensitivity analysis
Per protocol baseline covariates and outcome values at follow-up are reported in Table 3 . In the IPT weighted sample, all baseline covariates had standardized differences less than 0.25. After applying IPTO weights, the frequency of remission at follow-up for dual-action treatment episodes was 40% compared to 32% for singleaction treatment episodes, however the difference was not statistically significant. The IPTO weighted mean depression severity was lower, but not statistically different, for dual-action treatment episodes compared to single-action treatment episodes (6.9 vs 8.0). Table 4 contains the results of the IPTO weighted generalized linear models. Dualaction treatment episodes had 1.33 times the odds of ending in remission compared to single-action treatment episodes (OR=1.33, 95% CI 0.55-3.21), but this result was not statistically significant. The finding for the mean difference in depression symptom severity between treatment groups was also not statistically significant (β=-0.7, 95% CI -3.2-1.7).
Discussion
This is the first comparative effectiveness study we are aware of that compared dual-action to single-action antidepressants for the treatment of depression in PLWHA using data outside clinically controlled environments. We found no evidence to support 14 our hypothesis that dual-action antidepressants were more effective than single-action antidepressants in this population. This finding was the same in both intent-to-treat and per protocol analyses.
Our data suggest that therapeutic changes may have underestimated the effectiveness of dual-action relative to single-action antidepressants in intent-to-treat analyses. Specifically, post-index measures reveal that patients in dual-action treatment episodes tended to discontinue earlier and switch or augment more frequently (see Supplemental Online Appendix). More frequent changes could be due to lack of treatment response or intolerance of side effect profiles. Unfortunately, we did not have
measures to indicate what precipitated these changes. However, comparative effectiveness is intended to incorporate factors such as treatment alterations, therefore based on our data, overall effectiveness appears comparable between dual-action and single-action antidepressants.
Our results are consistent in part with the only study in the field of HIV/AIDS that we identified which compared antidepressants included in our investigation (Patel, 2013) . Similar to Patel et al. (2013) , no differences were observed in remission from depression between dual-action and single-action antidepressants. However, contrary to our findings, Patel et al. (2013) did detect a difference in depression symptom level at follow-up. The discrepancy in findings for depression symptom level could be due to differences in the survey instruments used for assessing depression (HAM-D vs PHQ-9). Additionally, the differences observed by Patel et al. (2013) occurred at week 8, whereas our follow-up observation occurred on average 184 days (26 weeks) from the index date.
In terms of research outside the field of HIV/AIDS, our results are in line with the findings from an Agency for Healthcare Research and Quality systematic review which concluded there were no advantages between different classes of antidepressants (Gartlehner et al., 2011) . However, our findings differed with Bradley and Lenox-Smith (2013) which concluded that dual-action serotonin-norepinephrine reuptake inhibitors (e.g. duloxetine) demonstrated greater efficacy compared to single-action SSRIs in more severe cases of depression (Bradley and Lenox-Smith, 2013 ). Had we limited dual-action treatment episodes to include only serotonin-norepinephrine reuptake inhibitors, we could make a more definitive comparison with Bradley and Lenox-Smith (2013) . However, we were unable to identify an adequate number of serotoninnorepinephrine reuptake inhibitor treatment episodes to define our intervention in this manner (see Supplemental Online Appendix for the specific medications identified in this study).
It is also important to note the low frequency of remission we observed for all patients in this study. Only 32% and 34% in total achieved remission at follow-up in the intent-to-treat and per protocol analysis, respectively (See Tables 1 and 3) . Our results are similar to prior estimates of remission rates (28%) in real world conditions . However, 32% is well below commonly observed remission rates in randomized controlled trials (median of 72%) . The differences in outcomes between research and standard practice environments suggests that there is potential for improvement when treating depression outside controlled settings. An additional implication is that remission may not always be possible and less aggressive treatment goals may be more realistic. Specifically, patients in our study may have experienced substantial reductions in symptom severity but still not fall below the PHQ-9 definition of remission. A mean PHQ-9 score of 8 was observed at follow-up in our analysis. A score of 8 is still indicative of mild depression, however, the patient may have experienced a significant improvement in depression severity after initiating treatment compared to baseline levels. Yet due to inconsistent availability of a pretreatment PHQ-9 measure in our dataset, we were unable to examine change in PHQ-9 score as an outcome.
Missing or unavailable data was the most significant limitation we faced. We were unable to control for baseline depression severity because, as noted above, so few patients had a recorded PHQ-9 within the washout period. Given this data limitation, we chose not to require a baseline PHQ-9 as an inclusion criterion. This decision increased the probability of unknown bias in the estimation of treatment effects due to potential differences in depression severity at baseline. One possible reason baseline depression severity would differ by treatment group is because several medications included in our analysis can be used for conditions other than depression. Bupropion (dual-action) is known to be used for smoking cessation (PDR, 2015b) . Likewise, paroxetine (single-action) can be used for social anxiety disorder (PDR, 2015a).
Unfortunately, treatment indication was not available in the data, therefore we cannot be certain that depression was the primary concern driving the initiation of antidepressant treatment. However, all included medications have a primary indication for depression treatment and are commonly used to treat depression in this population. Additionally, we sought to address this indication bias by limiting the sample to patients with a recorded diagnosis of depression in their medical record. Nevertheless, even though CNICS has a rigorous method for verifying diagnosis data (CNICS, 2014b), using such data raises the potential for miss-classification bias stemming from coding and reporting errors as well as missed diagnoses.
In addition to unobserved depression severity at baseline, we also encountered a significant number (58% of the treatment episodes) of missing PHQ-9s during the follow-up period. Given we could not rule out the possibility that depression severity was related to missing a PHQ-9 at follow-up, we chose to employ sophisticated statistical methods, specifically IPO weights to address this limitation. While IPO weighting would not necessarily eliminate all the bias stemming from missing outcomes, it is a stronger approach than a complete case analysis which assumes that the missing data introduce no bias.
Several other important treatment selection factors exist that could have confounded our findings. For example, given literature suggests that single-action medications are the most commonly prescribed antidepressants for depression in PLWHA (Freudenreich et al., 2010) , clinicians may be more experienced in managing this group of medications. Greater familiarity with these medications could improve the effectiveness of single-action antidepressants thereby biasing the results towards the null, assuming dual-action antidepressants are indeed more effective. Physician specialty (e.g. psychiatrists) could also influence treatment selection as this factor could be indicative of experience with a greater variety of antidepressants. Indeed, we did observe that participants initiating dual-action antidepressants were somewhat more likely to have seen a psychiatrist during the follow-up period compared to participants in single-action treatment episodes (39% vs 31%) (Online Supplemental Appendix).
However, appointment data also suggests that approximately 59% of the dual-action treatment episodes were administered by a prescribing physician other than a psychiatrist. These data indicate that non-specialists (e.g. HIV primary care physicians) also possess a level of comfort utilizing a variety of antidepressants including both dualaction and single-action medications. Ultimately, the potential impact of clinician experience and specialty described above is unobserved, therefore we used IPT weights to balance treatment groups on an observed appointment with a psychiatrist in the washout period. This measure may be a crude indicator of whether or not the prescribing physician specialized in the treatment of psychiatric disorders. However, our approach only partially addressed this issue as data was not available that confirmed the actual physician prescribing the medication.
An additional unobserved factor that could have biased our results is the selection of one type of antidepressant over another based on potential drug interactions between ART and antidepressants. While research indicates the pharmacokinetics of citalopram, escitalopram, duloxetine and mirtazapine is not known to be significantly altered by ART (Adams et al., 2012; Hill and Lee, 2013) , interactions have been identified between the remaining antidepressants and certain protease inhibitors and non-nucleoside reverse transcriptase inhibitors (Hill and Lee, 2013 ).
However, the potential impact of the drug interactions (potentiation or inhibition) varied by antidepressant and ART combination across both treatment groups, therefore we were unable to assess the effect of this factor in the present study.
A further limitation arose from the fact we were not able to measure adherence to antidepressant treatment. Overestimation and underestimation is possible with this factor depending on which group had the higher likelihood of non-adherence. We found no literature that specifically addressed differential rates of adherence based on how we classified antidepressants. However, the absence of literature does not indicate there is no difference. Therefore, we cannot speak thoroughly to the impact of this unobserved factor.
Finally, we were limited by how we operationalized the intervention. First we were unable to adequately define receipt of non-pharmacological treatment. The approach we took was to create a weight on a variable indicating the presence of an appointment with a mental health specialist at the CNICS clinic. However, we do not know the type and quality of therapy provided. Moreover, this approach only identifies a sub-set of patients receiving non-pharmacological treatment because the cohort can seek this type of treatment elsewhere. Secondly, data limitations prevented us from determining the consistency of adequate dosing across treatment groups.
Despite these limitations, this study makes several significant contributions to the field of psychiatric HIV/AIDS research. First, while our data did not support the hypotheses for differential effectiveness, the purpose of a comparative effectiveness study is to enhance certainty in treatment decisions. Our study provides evidence that suggests differential effectiveness is not a reason to prefer dual-action antidepressants over single-action antidepressants, and medication choice can be driven by other factors such as patient preference, side effects, costs and provider familiarity. Second, this is the first study to address the question of antidepressant comparative effectiveness in a sample limited to PLWHA using data collected outside of controlled clinical trials. Given our results show achieving remission from depression in real world 20 settings is difficult for PLWHA, this study highlights the importance for continued comparative effectiveness research in this field. Third, this study draws attention to the data challenges faced when conducting comparative effectiveness research. Our approach to dealing with data limitations should prove useful to other investigators.
There are several future research projects that would logically flow from our present study. Given prior literature has identified citalopram as one of the most commonly used antidepressants in PLWHA (Freudenreich et al., 2010) , future studies could compare the effectiveness of individual antidepressants against this medication.
This would help inform the validity of the current practice. Additionally, future investigations are warranted that aim to increase the probability that patients start regimens requiring minimal adjustments (switching, augmenting) and achieve remission in the shortest time frame. Such research could circumvent the negative interaction between depression and HIV/AIDS. Finally, the low rates of remission observed in this study highlight the need for on-going closely managed antidepressant therapy in PLWHA. In light of this fact, research that compares the long-term effectiveness of dual-action and single-action antidepressants is necessary to identify potential variations in treatment outcomes that may arise over an extended period of time.
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Footnotes
